Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some predictions for tomorrows earnings release. Q1 is usually light so I'll say loss of 1 - 2 cents a share. I'm also expecting some significant positive news. That's my story and I'm sticking to it.
Kiwi,
Aren't you overthinking this? Why wouldn't AMRN just create new labels for a generic version right on the existing assembly line? Simple manufacturing. Same pill, different bottle. Price slightly lower. Additional costs are almost nothing. Use up more API and the auto-switching to GenCepa competes with the Hikma's of the world. If we're already price competitive, minimal price change is needed.
Agreed.....and I couldn't resist grabbing another 500 shares at 2.81
CVD is still the number one cause of death in the WORLD. I hope to one day own stock in a drug that improves the chances of survival for those with CVD
We are profitable
Not to mention 100s of millions in tax loss carry forwards to offset profits.
Hey AMRN management, get off your arses and respond to an article like this. We are aware of a safe, effective medicine that reduces your risk of having that first heart attack, or second, or third.....
https://www.yahoo.com/gma/aspirin-no-longer-recommended-prevent-150011569.html
Major....... also is the fact the Elon Musk will now take twitter private it it won't be a liberal information censorship tool. The adults are making progress.
This could be my week?
73640
I'm certainly in favor of it. Are you against anyone who wants do everything they can to reduce their CV health risks? Care to explain that? Based on all the anecdotal evidence that V has anti-inflammatory properties and has a proven safety profile. Why would you want to deny this person?
74,640
"Therefore, the committee concluded that icosapent ethyl is not recommended for reducing the risk of cardiovascular events in people with elevated
triglycerides"
So....what did the committee consider to be elevated triglycerides? Obviously the market took this news with a big yawn.
Hey Novartis....... here's an idea for you AMRN
https://finance.yahoo.com/m/3449a2da-587e-3077-ab07-96328019d7df/novartis-shakes-up-structure.html
76640
Love it....
If I remember correctly, JT always said Q1 was the lightest script quarter due to most patient co-payment deductibles being met during Q1 and they would hold off getting their refills until Q2 and beyond.
74640
Stupid oligarchs. Don't they understand that if they invest their money with Hunter B's company, they'll suffer no repercussions.
Nice finds dogn...... there seems to be more and more outreach and positive information. And they'll tell two friends and they'll tell two friends....we will get there!
Well Raf, if you would have won again, we'd request a urine sample as a cheating scandal would be top of mind.
77777
Well Marjac.... lot's of parallels for sure. You've got the ball with a long drive ahead and time running out. This is why we traded for you and a victory secures your place in the justice hall of fame.
Did my donation.... go get em Marjac
76240
True, as I am already invested in AMRN and am fine with my investment based on the aforementioned reasons. If you were to suggest another stock with the same characteristics, I would then qualify as an investor not yet invested in that stock. It would be very appealing. Especially at $3 share.
If I think like an investor who has not yet invested in AMRN, I would find it very appealing risk wise. They are profitable with no debt. Not growing in the US but I know why. They are growing in the rest of the world which is just getting started..... they have $ 500 million in cash and the only drug approved bt the FDA for CV risk reduction. Seems worth investing in to me.
Interesting observation BB...... here's my take on what he would say if he could...
"We look forward to sharing more details on this partnership in 2022 once our acquisition by Pfizer has been completed"
A total market beat down...... just ride it out.
I meant to say Fortune favors the bold....... not History
Agreed..... but Du and Covid also derailed progress in a big way. History favors the bold so I hope you have been accumulating cheap shares along the way. We are now a profitable company with no debt. Imagine the possibilities if we do execute and the public starts to get a clue of what Vascepa is and does.
louie, shouldn't this date be 2022?
The filing deadline for the Certiori is May 16, 2021.
Great article P-dude. Thanks for sharing and very promising.
Great story Birdbrain...... a flicker of light in the darkness.
We are a tough crowd.... we own a beaten down stock in a 1 drug company... but we have:
1. New management team
2. We are Profitable
3. Have 1/2 billion dollars in cash.
4. No debt
5. Just now expanding sales into the EU
6. Well known activist investor
7. Pending approval in China
8. The pandemic is nearing it's conclusion in the US
9. Did I mention that we are profitable with no debt?
Better days await.
JRoon, most of what he says is either negative or just off base. I'm sure AMRN decided to publicly announce this over the past couple of months because "it's a non-starter". To me, it's a US market mic drop if it existed today. Primarily because of the Du decision.
No argument here Abe.... you could probably buy a list from Amazon of all people who have purchased Fish Oil and market directly to them as to why they are wasting their money.
This data is protected.
HIPAA, the Healthcare Insurance Portability and Accountability Act, was signed into law on August 21, 1996. HIPAA’s overarching goal is to keep patients’ protected health information (PHI) safe and secure, whether it exists in a physical or electronic form.
Trust me....I'm not sticking up for management..... they blew it many times over. If we didn't have the Du decision, the combo pills wouldn't be as important. Prior to the Du decision, you'd want to be statin independent and could care less what statin a patient was taking. Now the pairing is more complicated. So let's get Pfizer to buy this thing and supercharge their statin portfolio.
Sleven, why not? What am I missing? It serves a couple of incredibly valuable purposes. Today your Dr would write a CV risk reduction prescription for Vascepa ( Icosapent Ethyl). The pharmacist may fill it with gV. A combo pill most likely will not be called Vascepa and it certainly won't just be Icosapent Ethyl. So your Dr will write a prescription for a patented CV risk reduction drug called EPAstatin. Whatever the chemical compound is, it can't be filled with a gV. Let the generics fight it out amongst themselves, Amarin's V, and the other TG lowering drug makers for the TG lowering indication only. The other valuable purpose is to reduce the number of pills taken for this therapeutic. At least my assumption is less pills.
Fortunately I don't. I can't get a prescription for V. Put statin medication in a V pill does translate to less pills don't you think?